Gingivitis InfectionNCT07696364
Chlorhexidine (CHX) Mouthwash With or Without an Anti-Discoloration System (ADS) During Experimental Gingivitis
A study testing Experimental gingivitis model in people with Gingivitis Infection, run by University of Bern at 1 site in Switzerland.
Trial summary
Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Gingivitis Infection
- What is being tested?
- Experimental gingivitis model
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 33 participants
- Where
- 1 siteSwitzerland
- Study dates
- 3 Aug 2026to 7 Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- systemically healthy,
- non-smoker, former smokers > 5 years,
- at least 24 teeth,
- clinical diagnosis of periodontal health or gingivitis as determined by pocket probing depth not exceeding 4 mm with concomitant bleeding on probing.
Who cannot join
- clinically visible carious lesions,
- systemic antibiotics within 3 months prior to enrolment
- vulnerable persons
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Department of Periodontology, University of Bern
Bern, Canton of Bern, 3010
About this study
Official title: Protocol Title Evaluation of the Anti-septic Effect of a Chlorhexidine (CHX) Mouthwash With or Without an Anti-Discoloration System (ADS) Compared to Placebo, During Experimental Gingivitis
Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation. The design enables a study to be performed over 35 days in a well-controlled manner. So far, it is the most accurate clinical study model to access how medication or compounds in dentifrices affect plaque accumulation and gingival inflammation.
Read the detailed description
Chlorhexidine is the most effective anti-plaque agent to date. It was more widely used in medicine and surgery. Löe and Schiött (1970) firstly studied its application in dentistry. The study showed that rinsing for 60 seconds twice per day with 10ml of a 0.2% chlorhexidine gluconate solution in the absence of normal tooth cleaning, inhibited plaque regrowth and the development of gingivitis. Because chlorhexidine is a bis-biguanide with a strong base and cationic, it reacts with anions, which is related to its antimicrobial activity. It has no systemic toxicity from topical application or ingestion. However, two pronounced side effects - superficial staining of the teeth and altered taste perception - were recognized almost immediately. This may compromise patient compliance for esthetic reasons. Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation. The design enables a study to be performed over 35 days in a well-controlled manner. So far, it is the most accurate clinical study model to access how medication or compounds in dentifrices affect plaque accumulation and gingival inflammation.
Chlorhexidine is the most effective anti-plaque agent to date. It was more widely used in medicine and surgery. Löe and Schiött (1970) firstly studied its application in dentistry. The study showed that rinsing for 60 seconds twice per day with 10ml of a 0.2% chlorhexidine gluconate solution in the absence of normal tooth cleaning, inhibited plaque regrowth and the development of gingivitis. Because chlorhexidine is a bis-biguanide with a strong base and cationic, it reacts with anions, which is related to its antimicrobial activity. It has no systemic toxicity from topical application or ingestion. However, two pronounced side effects - superficial staining of the teeth and altered taste perception - were recognized almost immediately. This may compromise patient compliance for esthetic reasons. Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation.
During the study period, participants will be asked to rinse with the mouthrinse sample or the placebo for 60 seconds twice daily, under video supervision (participants send in video recordings of their rinsing to control adherence to the protocol). A dental assistant, unaware of the study's purpose, will distribute the samples. The containers will be unlabeled, ensuring that both the participants and examiners are blinded to group allocation.
At Days 0, 7, 14 and 21 of the experiment, clinical examinations will be performed from central incisors to the second molars in each participant. The Discoloration Index (DI17) will be recorded at three aspects on each tooth (mesial, buccal and distal). The criteria for the Discoloration Index (DI) are indicated in Table 1. Plaque and Gingivitis Indices will be assessed at 4 aspects of each tooth (mesial, buccal, distal and lingual) using the criteria of the Plaque Index system (PlI) (Silness \& Löe 1964) and the Gingival Index System (GI) (Löe \& Silness 1963) 16, 18. At each visit, the parameters will be assessed by the same examiner, who will be masked by the allocation of the test and control to avoid examiner bias and calibration bias.
Upon completion of the experimental period, mechanical daily plaque control measures will be re-instated and the participants will be re-examined after 3 weeks to ensure their periodontal health. Following the experimental period, another professional cleansing will be performed to remove plaque and possible stain on the teeth. At day 35 the participants will be checked again.
- Conditions
- Gingivitis Infection
- Being tested
- Experimental gingivitis model
- Keywords
- experimental gingivitis, gingivitis model, mouth-rinses with anti-discoloration system
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Experimental gingivitis modelOther
Participants will abolish all measures for mechanical plaque control for a period of 3 weeks according to the experimental gingivitis model.
| Study group | Role | What they receive |
|---|---|---|
| Placebo Group | Placebo comparator | Group P rinses twice daily with 10 ml of a placebo (pure water with flavored additive) solution Receives: Other: Experimental gingivitis model |
| Group T1 | Experimental | Group T1 rinses twice daily with 10 ml of 0.12% chlorhexidine solution with ADS (Anti-Discoloration System) solution (Curasept ADS 212) Receives: Other: Experimental gingivitis model |
| Group T2 | Experimental | Group T2 rinses twice daily with 10 ml of 0.12% chlorhexidine with HA (Hyaluronic Acid) Receives: Other: Experimental gingivitis model |
What is being measured
The primary outcome is the main question the study is designed to answer.
Severity of gingival inflammation, assessed by the Gingival Index by Löe and Silness 1963
The index is a scoring system 0, 1, 2, or 3 where 0 is defining normal gingiva to 3 representing severe inflammation with spontaneous bleeding
Measured: at day 21
Secondary outcomes (6)
Severity of gingival inflammation, assessed by the Gingival Index by Löe and Silness 1963
The index is a scoring system 0, 1, 2, or 3 where 0 is defining normal gingiva to 3 representing severe inflammation with spontaneous bleeding
Measured: at day 0, 7, 14, and 35
Plaque accumulation, assessed by the Plaque Index Silness and Löe 1994
The index is a scoring system assessing the plaque at 4 surfaces of the teeth, starting at 0 for no plaque visible to 3 with an abundance of plaque creating a thick layer that fills the interdental space.
Measured: at day 0, 7, 14, 21 and 35
Staining assessed by the Discoloration index
The discoloration is an index from 0: no discoloration to 3: Heavy brown and black discoloration over the entire extent of the tooth surface, black discoloration predominantly on the interproximal surfaces
Measured: at day 0, 7, 14, 21 and 35
Oral scan
Oral scans will be performed to study changes in gingival texture, volume and colour or other changes
Measured: at day 0, 21 and 35
Microbiological changes
Changes in 8 periodontopathogens will be assessed by Multiplex PCR
Measured: at day 0, 21 and 35
Characterisation of host- and microbiome-derived metabolites
From selective participants, host-derived metabolites will be assessed by untargeted liquid chromatography-mass spectrometry (LC-MS) to study molecular changes throughout disease progression and possible relationships with other generated datasets.
Measured: at day 0, 21 and 35
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2026
- Study start3 Aug 2026
- Primary completion7 Sep 2026
- Study completion7 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gingivitis InfectionStudies of the same condition, open and under way.
- More trials run by University of BernThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a single-center, double-blind, parallel, randomized controlled trial (RCT) conducted on 33 volunteers recruited by the University of Berne School of Dental Medicine (aged 18-40 years) with a documented healthy periodontium
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 33 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Bern
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07696364
- Sponsor's protocol ID
- V4ExpAugGingivitis
- Status last verified
- Aug 2026
- First submitted
- 6 Jul 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Protocol Title Evaluation of the Anti-septic Effect of a Chlorhexidine (CHX) Mouthwash With or Without an Anti-Discoloration System (ADS) Compared to Placebo, During Experimental Gingivitis
- ClinicalTrials.gov ID
- NCT07696364
- Acronym / sponsor ID
- V4ExpAugGingivitis
- Conditions
- Gingivitis Infection
- Keywords
- experimental gingivitis, gingivitis model, mouth-rinses with anti-discoloration system
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 33 participants (actual)
- Lead sponsor
- University of BernUniversity, hospital or other
- Study start
- 3 Aug 2026 (actual)
- Primary completion
- 7 Sep 2026 (actual)
- Study completion
- 7 Sep 2026 (actual)
- First posted
- 10 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation. The design enables a study to be performed over 35 days in a well-controlled manner. So far, it is the most accurate clinical study model to access how medication or compounds in dentifrices affect plaque accumulation and gingival inflammation.
Detailed description
Chlorhexidine is the most effective anti-plaque agent to date. It was more widely used in medicine and surgery. Löe and Schiött (1970) firstly studied its application in dentistry. The study showed that rinsing for 60 seconds twice per day with 10ml of a 0.2% chlorhexidine gluconate solution in the absence of normal tooth cleaning, inhibited plaque regrowth and the development of gingivitis. Because chlorhexidine is a bis-biguanide with a strong base and cationic, it reacts with anions, which is related to its antimicrobial activity. It has no systemic toxicity from topical application or ingestion. However, two pronounced side effects - superficial staining of the teeth and altered taste perception - were recognized almost immediately. This may compromise patient compliance for esthetic reasons. Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation. The design enables a study to be performed over 35 days in a well-controlled manner. So far, it is the most accurate clinical study model to access how medication or compounds in dentifrices affect plaque accumulation and gingival inflammation.
Chlorhexidine is the most effective anti-plaque agent to date. It was more widely used in medicine and surgery. Löe and Schiött (1970) firstly studied its application in dentistry. The study showed that rinsing for 60 seconds twice per day with 10ml of a 0.2% chlorhexidine gluconate solution in the absence of normal tooth cleaning, inhibited plaque regrowth and the development of gingivitis. Because chlorhexidine is a bis-biguanide with a strong base and cationic, it reacts with anions, which is related to its antimicrobial activity. It has no systemic toxicity from topical application or ingestion. However, two pronounced side effects - superficial staining of the teeth and altered taste perception - were recognized almost immediately. This may compromise patient compliance for esthetic reasons. Recently, a chlorhexidine product with an anti-discoloration system (ADS) was launched in the market. A comparative study was done to confirm the effectiveness of 0.2% chlorhexidine with ADS. The study was single-blinded. In the experimental period, volunteers maintained their usual oral hygiene habits, besides, they rinsed twice daily with mouthwash (0.2% chlorhexidine) with or without ADS. Obviously, subject's home oral hygiene may become a major confounder of plaque accumulation. Although the effect of ADS is statistically significant, the ability of this new product to prevent plaque accumulation and gingivitis remained highly questionable.
Hence, controversy exists about the clinical efficacy of the chlorhexidine products with ADS. Consequently, a clinical validation of such products appears necessary. In the present study, the 21-day experimental gingivitis model will be used. This model is an established non-invasive model in humans for investigating the induction and resolution of inflammation in response to increasing bacterial accumulation.
During the study period, participants will be asked to rinse with the mouthrinse sample or the placebo for 60 seconds twice daily, under video supervision (participants send in video recordings of their rinsing to control adherence to the protocol). A dental assistant, unaware of the study's purpose, will distribute the samples. The containers will be unlabeled, ensuring that both the participants and examiners are blinded to group allocation.
At Days 0, 7, 14 and 21 of the experiment, clinical examinations will be performed from central incisors to the second molars in each participant. The Discoloration Index (DI17) will be recorded at three aspects on each tooth (mesial, buccal and distal). The criteria for the Discoloration Index (DI) are indicated in Table 1. Plaque and Gingivitis Indices will be assessed at 4 aspects of each tooth (mesial, buccal, distal and lingual) using the criteria of the Plaque Index system (PlI) (Silness \& Löe 1964) and the Gingival Index System (GI) (Löe \& Silness 1963) 16, 18. At each visit, the parameters will be assessed by the same examiner, who will be masked by the allocation of the test and control to avoid examiner bias and calibration bias.
Upon completion of the experimental period, mechanical daily plaque control measures will be re-instated and the participants will be re-examined after 3 weeks to ensure their periodontal health. Following the experimental period, another professional cleansing will be performed to remove plaque and possible stain on the teeth. At day 35 the participants will be checked again.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- This study is a single-center, double-blind, parallel, randomized controlled trial (RCT) conducted on 33 volunteers recruited by the University of Berne School of Dental Medicine (aged 18-40 years) with a documented healthy periodontium
| Arm | Type | Receives |
|---|---|---|
| Placebo Group | Placebo comparator | Other: Experimental gingivitis modelGroup P rinses twice daily with 10 ml of a placebo (pure water with flavored additive) solution |
| Group T1 | Experimental | Other: Experimental gingivitis modelGroup T1 rinses twice daily with 10 ml of 0.12% chlorhexidine solution with ADS (Anti-Discoloration System) solution (Curasept ADS 212) |
| Group T2 | Experimental | Other: Experimental gingivitis modelGroup T2 rinses twice daily with 10 ml of 0.12% chlorhexidine with HA (Hyaluronic Acid) |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- systemically healthy,
- non-smoker, former smokers > 5 years,
- at least 24 teeth,
- clinical diagnosis of periodontal health or gingivitis as determined by pocket probing depth not exceeding 4 mm with concomitant bleeding on probing.
Key exclusion criteria (3 listed)
- clinically visible carious lesions,
- systemic antibiotics within 3 months prior to enrolment
- vulnerable persons
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Experimental gingivitis modelParticipants will abolish all measures for mechanical plaque control for a period of 3 weeks according to the experimental gingivitis model. | Other | Group T1, Group T2, Placebo Group |
Primary outcome
Severity of gingival inflammation, assessed by the Gingival Index by Löe and Silness 1963
Time frame: at day 21
The index is a scoring system 0, 1, 2, or 3 where 0 is defining normal gingiva to 3 representing severe inflammation with spontaneous bleeding
6 secondary outcomes
Severity of gingival inflammation, assessed by the Gingival Index by Löe and Silness 1963
Time frame: at day 0, 7, 14, and 35
Plaque accumulation, assessed by the Plaque Index Silness and Löe 1994
Time frame: at day 0, 7, 14, 21 and 35
Staining assessed by the Discoloration index
Time frame: at day 0, 7, 14, 21 and 35
Oral scan
Time frame: at day 0, 21 and 35
Microbiological changes
Time frame: at day 0, 21 and 35
Characterisation of host- and microbiome-derived metabolites
Time frame: at day 0, 21 and 35
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Gingivitis Infection
Enrolling by invitation
Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolerance in People With Gingivitis
Microbiome, Cytokines
Active, not recruitingPhase 3
A Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis
Plaque, Gingivitis
Not yet recruiting
Effectiveness of Personalized Digital Oral Health Intervention in Patients With Fixed Orthodontic Appliances.
Oral Hygiene in Patients With Fixed Orthodontic Appliances, Dental Plaque
Not yet recruitingPhase 2
Efficacy of Thymus Vulgaris Mouthwash in the Management of Biofilm-Induced Gingivitis
Plaque-Induced Gingivitis
Not yet recruitingPhase 3
Periodontal Disease and Small Vulnerable Newborns in Rural Nepal: A Community-based Trial
Preterm Birth, Low Birth Weight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Experimental gingivitis model in people with Gingivitis Infection, run by University of Bern at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Severity of gingival inflammation, assessed by the Gingival Index by Löe and Silness 1963 (time frame: at day 21). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.